Biomea Fusion, Inc. is a clinical-stage diabetes and obesity medicines company focused on discovering and developing oral small molecule drugs. Founded in 2017, the company operates two core programs: icovamenib (formerly BMF-219), a covalent menin inhibitor in clinical trials for type 1 and type 2 diabetes and obesity, and BMF-650, an investigational next-generation oral GLP-1 receptor agonist for obesity treatment.
expected 2026-12-22
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-24 | 2025-12-31 | 0001193125-26-121825 | EDGAR | 90K words |
| 2025-03-31 | 2024-12-31 | 0000950170-25-047775 | EDGAR | 89K words |
| 2024-03-28 | 2023-12-31 | 0000950170-24-038026 | EDGAR | 93K words |
| 2023-03-28 | 2022-12-31 | 0000950170-23-010312 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0001564590-22-007624 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-05 | 2026-06-30 | 0001193125-26-335085 | EDGAR | 64K words |
| 2025-11-04 | 2025-09-30 | 0001193125-25-264679 | EDGAR | 66K words |
| 2025-08-05 | 2025-06-30 | 0000950170-25-103041 | EDGAR | 64K words |
| 2025-05-05 | 2025-03-31 | 0000950170-25-063543 | EDGAR | 60K words |
| 2024-10-29 | 2024-09-30 | 0000950170-24-118366 | EDGAR | 61K words |
| 2024-07-31 | 2024-06-30 | 0000950170-24-088584 | EDGAR | 61K words |
| 2024-05-02 | 2024-03-31 | 0000950170-24-052082 | EDGAR | 59K words |
| 2023-10-30 | 2023-09-30 | 0000950170-23-056381 | EDGAR | 64K words |
| 2023-07-31 | 2023-06-30 | 0000950170-23-035946 | EDGAR | 63K words |
| 2023-05-02 | 2023-03-31 | 0000950170-23-016700 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0000950170-22-022607 | EDGAR | — |
| 2022-08-01 | 2022-06-30 | 0000950170-22-013678 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-22 | 0001193125-26-397870 | EDGAR | 1K words |
| 2026-08-05 | 0001193125-26-335073 | EDGAR | 3K words |
| 2026-03-24 | 0001193125-26-121811 | EDGAR | 2K words |
| 2026-02-25 | 0001193125-26-068375 | EDGAR | 5K words |
| 2026-01-14 | 0001193125-26-012908 | EDGAR | 5K words |
| 2025-11-04 | 0001193125-25-264631 | EDGAR | 3K words |
| 2025-10-07 | 0001193125-25-233614 | EDGAR | 1K words |
| 2025-10-06 | 0001193125-25-231903 | EDGAR | 2K words |
| 2025-08-05 | 0000950170-25-103023 | EDGAR | 3K words |
| 2025-07-24 | 0001193125-25-163815 | EDGAR | 1K words |
107 total filings indexed. 80 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001840439 |
| Ticker | BMEA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.biomeafusion.com |
| Listed | 2021-04-16 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/BMEA (~200 tokens, structured JSON with cryptographic provenance)